Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty

NCT00463723 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

OTHER

Sponsor class

Conditions

Penetrating Keratoplasty

Interventions

DRUG: FK506 0.06% (eye drops)

Sponsor

University Hospital Freiburg

Collaborators

[object Object]